BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Robillard R" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Obstructive Sleep Apnea Risk and Mental Health Conditions Among Older Canadian Adults in the Canadian Longitudinal Study on Aging | Kendzerska T; Mallick R; Li W; Robillard R; Taler V; Webber C; Saymeh M; Dang-Vu TT; Tanuseputro P; Fiedorowicz JG; | 41632160 HKAP |
| 2 | The complex association between bedtime screen use and adult sleep health | Vézina-Im LA; Morin CM; Chen S; Ivers H; Carney CE; Chaput JP; Dang-Vu TT; Davidson JR; Robillard R; | 40713469 HKAP |
| 3 | Efficacy of cognitive behavioral therapy for insomnia and lemborexant medication for different subtypes of chronic insomnia: study protocol for a randomized controlled trial | Chen SJ; Ivers H; Dang-Vu TT; Shapiro CM; Carney CE; Robillard R; Morin CM; | 40346496 HKAP |
| 4 | Trends in nighttime insomnia symptoms in Canada from 2007 to 2021 | Chaput JP; Morin CM; Robillard R; Carney CE; Dang-Vu TT; Davidson JR; Tomkinson GR; Lang JJ; | 39556998 HKAP |
| 5 | Delphi consensus recommendations for the management of chronic insomnia in Canada | Morin CM; Khullar A; Robillard R; Desautels A; Mak MSB; Dang-Vu TT; Chow W; Habert J; Lessard S; Alima L; Ayas NT; MacFarlane J; Kendzerska T; Lee EK; Carney CE; | 39481275 HKAP |
| 6 | Prevalence of insomnia and use of sleep aids among adults in Canada | Morin CM; Vézina-Im LA; Chen SJ; Ivers H; Carney CE; Chaput JP; Dang-Vu TT; Davidson JR; Belleville G; Lorrain D; Horn O; Robillard R; | 39369578 HKAP |
| 7 | Economic burden of insomnia symptoms in Canada | Chaput JP; Janssen I; Sampasa-Kanyinga H; Carney CE; Dang-Vu TT; Davidson JR; Robillard R; Morin CM; | 36319579 PERFORM |
| Title: | Economic burden of insomnia symptoms in Canada | ||||
| Authors: | Chaput JP, Janssen I, Sampasa-Kanyinga H, Carney CE, Dang-Vu TT, Davidson JR, Robillard R, Morin CM | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/36319579/ | ||||
| DOI: | 10.1016/j.sleh.2022.09.010 | ||||
| Publication: | Sleep health | ||||
| Keywords: | Economic cost; Health care cost; Insomnia; Public health; | ||||
| PMID: | 36319579 | Category: | Date Added: | 2022-11-02 | |
| Dept Affiliation: |
PERFORM
1 Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Ontario, Canada; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: jpchaput@cheo.on.ca. 2 School of Kinesiology and Health Studies, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada. 3 Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Ontario, Canada. 4 Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada. 5 Institut Universitaire de Gériatrie de Montréal and CRIUGM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, Quebec, Canada; PERFORM Centre, Center for Studies in Behavioral Neurobiology, Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, Quebec, Canada. 6 Department of Psychology, Queen's University, Kingston, Ontario, Canada. 7 The University of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada. 8 School of Psychology, Laval University, Quebec City, Quebec, Canada. |
||||
Description: |
Objective: To estimate health care and productivity costs associated with insomnia symptoms in Canadian adults. Methods: Three pieces of information were needed to calculate estimates based on a prevalence-based approach: (1) the pooled relative risk estimates of health outcomes consistently associated with insomnia symptoms obtained from recent meta-analyses of prospective cohort studies; (2) the direct (health care) and indirect (lost productivity due to premature mortality) costs of these health outcomes using the Economic Burden of Illness in Canada information; and (3) the prevalence of insomnia symptoms in Canadian men (18.1%) and women (29.5%) obtained from a nationally-representative survey. Results: The direct, indirect, and total costs of insomnia symptoms in Canada in 2021 were $1.9 billion, $12.6 million, and $1.9 billion, respectively. This value represents 1.9% of the overall burden of illness costs for 2021 in Canada. The 2 most expensive chronic diseases attributable to insomnia symptoms were type 2 diabetes ($754 million) and depression ($706 million). The main contributor to the costs for type 2 diabetes and depression was prescription drugs. A 5% decrease in insomnia symptoms (from 23.8% to 18.8%) would result in an estimated $353 million in avoided costs while a 5% increase in insomnia symptoms (from 23.8% to 28.8%) would result in an estimated $333 million in additional expenditures yearly. Conclusions: Insomnia symptoms greatly contribute to the economic burden of illness in Canada. Reducing the prevalence of insomnia symptoms would reduce its societal burden. |
